Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy.

Cancer Med · 2014 · PMC4101751 · PMID 24574357

Europe PMC DOI

hedged sentence

0.0850

closest p · 1.7× alpha

0.0850

boldest claim

The sentences

showed a trendP = 0.085so close (0.05 < p ≤ 0.1)

When evaluated among the non AC patients, the KM curves showed a trend for better OS in the MSKPN low-risk patients (log rank test P = 0.085) and the median survival time was estimated to be 6.58 years (95% CI: 3.13-Inf), and 3.06 (95% CI: 2.33–5.42), low- and high-risk patients, respectively.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.